

Supplementary Table 1. Demographic and clinical characteristics of the study cohort

	SARS-CoV2 Negative	SARS-CoV2 Positive	SARS-CoV2 Positive	P value**
	-	outpatients	Inpatients	Outpatients vs inpatients
number (<i>n</i>)	20	20	40	-
Female, <i>n</i> (%)	10 (50)	12 (60)	18 (45)	0.41
Age, years, median (IQR)	55.5 (15.6)	52.5 (12.75)	58.5 (6)	-
Body mass index (BMI)				
Normal Weight (<25), %	-	6.7*	15	0.66
Overweight/obese (>25), %	-	93.3*	85	0.66
Pre-diabetes, %	-	6.7*	22.5	0.25
Diabetes Mellitus (DM), %	-	6.7*	42.5	0.01
High blood pressure, %	-	33.3*	60	0.13
Asthma, %	-	13.3*	10	0.66
Hydroxychloroquine, %	-	6.7*	47.5	-
Remdesivir, %	-	-	15	-
Tocilizumab, %	-	-	17.5	-
Chronic Steroid Use, %	-	-	15	-
Acute Steroid Use, %	-	-	30	-
Plasma IV nutrition, %	-	-	0	-
Enteral nutrition use, %	-	-	40	-
Antibiotic administration, %	-	-	72.5	-
Ethnicity				
African American, <i>n</i> (%)	0	0	16 (40)	-
Hispanic or Latino	0	2 (10.0)	15 (37.5)	-
Caucasian, <i>n</i> (%)	3 (15.0)	13 (65.0)	7 (17.5)	-
Other, <i>n</i> (%)	2 (10.0)	1 (5.0)	1 (2.5)	-
Unknown, <i>n</i> (%)	15 (75.0)	4 (20.0)	1 (2.5)	-

*Based on 15 out of 20 donors with available data

** Fisher's exact test